Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Summary

To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.

Timeline

Start

2014-10-09

Primary completion

2017-10-04

Completion

2017-10-04

Outcome

Met primary endpoint

release “日本人女性に LF111 を投与した結果、良好な避妊効果が示された。” aska-pharma.co.jp ↗

Publications

• Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC Womens Health. 2020 Oct 2;20(1):218. doi: 10.1186/s12905-020-01080-9.

Drugs

Indications

No indication recorded.